|
|
Speakers 
 Frank Bedu Addo,
President and CEO,
PDS Biotechnology Corporation, USA
Dr. Bedu-Addo is the President and Chief Executive Officer of PDS Biotechnology Corporation. Prior to PDS Biotechnology Corporation, Dr. Bedu-Addo was hired by KBI BioPharma (Durham, NC) as a founding member and on the executive management team. As the Vice President of Drug Development, he was responsible for initiating and overseeing all drug and business development operations. He was also responsible for revenue generation and for profit and loss. He designed and spearheaded modification of the company’s business strategy in order to speed up revenue generation. The business strategy, instituted technologies and caliber of the drug development group enabled the company to compete successfully with the industry leaders in the biotechnology drug development market. Prior to KBI BioPharma, he also successfully started and headed up Cardinal Health’s (Somerset, NJ & RTP, NC) east coast biotechnology drug development operations. In both positions he oversaw client activities. Dr. Bedu-Addo has developed over 15 drug delivery and biotechnology-based drug products including vaccines at various clinical stages. He has worked on leading products such as Abelcet® and Peg-Intron®. He also performed pioneering work on the Stealth® Liposome Technology. He was involved with drug formulation, scale-up and process development at companies such as Schering-Plough, Elan (Formerly the Liposome Co.) and Akzo-Nobel. He has been invited world-wide to speak on various biotechnology drug development topics and has also acted as a consultant to several drug companies. Dr. Bedu-Addo has a BS and MS in Chemical Engineering, and PhD in Pharmaceutics. He obtained both his MS and PhD from the University of Pittsburgh.
|
 Michael Baijot,
Vice President, Worldwide Business Development & Strategic Alliances,
GlaxoSmithKline Biologicals, Belgium
Michel Baijot joined GSK Biologicals as Vice President Worldwide Business Development and Strategic Alliances in April 2005. He is a member of the Biologicals Management Team. In 1986, he began his professional career with SmithKline Biologicals in R&D as a scientist and completed his doctorate on the characterization of the Hepatitis B recombinant vaccine.
In 1991, Michel Baijot joined BioMériuex Belgium to hold various marketing and management positions. In 1995, he took the responsibility of Corporate Director of
BioMérieux, Boston, MA, as Head of the new Molecular Division of the group. Michel Baijot served as Vice President Business Development and Licensing at
Innogenetics from 2000 to 2005. Michel Baijot earned his Chemical Engineering degree and his Doctorate in
Biochemistry from the University of Louvain, Belgium.
|
 Zeng Beng,
Vice President,
China National Biotec Group (CNBG), China
Dr. Bing ZENG is Vice President of China National Biotec Group (CNBG) and responsible for international cooperation and business development of CNBG. Prior to joining CNBG in 2004, Dr. ZENG served in various multinational biotech and pharmaceutical companies including Boehringer Mannheim, Organon Teknika (a business unit of AKZO Nobel) and BIOMERIEUX for many years both in China and in Europe. Dr. Bing ZENG received his MBA degree from Nijenrode University (now named NIJENRODE BUSINESS UNIVERSITEIT), The Netherlands Business School in The Netherlands, and his Medical Degree from Beijing Medical University (now named The Medical School of Peking University) in Beijng, China. He practiced in China-Japan Friendship Hospital in Beijing as a Physician before he pursued his career in biotech Industry.
|
 David Buckley,
President,
David Buckley & Associates Pty Ltd
David Buckley started work as a laboratory cadet for Wyeth in Auckland, New Zealand in 1964, while studying at ATI at night to complete his degrees, and then transferred to Sydney Australia. He joined Burroughs Welcome and worked on projects such as Insulin manufacture, extraction, partial synthesis and quality control of cardioactive glycosides such as digoxin from Digitalus lanata, as well as mainstream pharmaceuticals. He then worked with ICI Pharmaceuticals in Sydney as QA Manager until 1984 when he joined the NSW Health Department, and the National Biologicals Standards Laboratory which was to become the Therapeutic Goods Administration. His major work there was GMP auditing and he helped steer through Blood Banking legislation and Codes of GMP, biologics inspections, and vaccines inspections.
He left in 2000 after 17 years as a Senior GMP Auditor to work as a consultant. He now has his own company (www.navigategmp.com) and his major clients include Medicines Sans Frontiers, UNICEF, WHO, UNIDO, World Bank and Bio Farma of Indonesia as well as pharmaceutical companies in three continents.
His work with UN agencies has involved various projects (including vaccines prequalification, for WHO ATT) and he has successfully completed missions for UN agencies in Cuba, Cyprus, Denmark, Vietnam, India, Nepal, Myanmar, Oman, Egypt, Iran, Nigeria, Thailand, China, North Korea, Indonesia, and Japan. His work with other clients has taken him to Taiwan, Hong Kong, South Korea, Malaysia, Singapore, Germany, UK, Costa Rica, Puerto Rica, USA, Canada, Mexico, New Zealand, as well as Australia where he is based.
He is a chemist and a microbiologist (from Otago New Zealand) and he is member of the Royal Australian Chemical Institute, he was admitted as a Member of the Australian Society for Microbiology in 1982, and he is a Fellow of the Quality Society Australian since 1984.
|
 Jacques M Cholat,
President,
sanofi pasteur International, France
|
 Supamit Chunsutiwat,
Senior Medical Advisor, Department of Disease Control,
Ministry of Public Health, Thailand
|
 John Clemens,
Director General,
International Vaccine Institute, Korea
Dr. John D. Clemens, Director General of the International Vaccine Institute (IVI), is an international expert on the evaluation of vaccines in developing countries. A graduate of Stanford (B.S.) and Yale (M.D.) Universities, Dr. Clemens is U.S.-Board Certified in Internal Medicine, and received his post-doctoral research training in clinical epidemiology at Yale. From 1983-88, he served as a research scientist at the International Centre for Diarrhoeal Disease Research, Bangladesh, where he led the first efficacy trial of an oral vaccine against cholera, and where he conducted additional research on measles vaccine. After returning to the U.S., he served as Chief of the Epidemiology Section of the Center for Vaccine Development of the University of Maryland, and then as Chief of the Epidemiology Branch of the National Institute of Child Health and Human Development , U.S. National Institutes of Health (NIH). While at NIH he was the Director of the first WHO Collaborating Centre for Vaccine Evaluation in Developing Countries. In 1999 he became the first Director-General of the IVI, a position which he continues to hold. During his tenure at the IVI, the IVI has grown from 10 to over 120 staff, its annual budget has increased from under $2 million to over $20 million, and the IVI has established field research programs on vaccines against enteric infections, invasive encapsulated bacterial infections, Japanese encephalitis, and dengue fever, and on vaccine safety in 22 developing countries of Asia, Africa, and Latin America. Dr. Clemens serves as an Adjunct Professor at the Johns Hopkins Bloomberg School of Public Health and at the Seoul National University School of Public health.
|
 Mahima Datla,
Vice President, Biotechnology and Projects,
Biological E
Ms Mahima Datla is Sr.Vice president for Bio-Technology and Projects Division in Biological E. Limited. She has been in charge for co-ordination of development of cell culture based in-activated Japanese encephalitis vaccines in India in partnership with Intercell of Austria, which is at the forefront of the industry. During her experience at BE, she has also been involved in strategy and business development functions.
Ms. Datla is an elected member of the Steering Committee for the DCVMN (Developing Countries Vaccine Manufacturers Network) since April 2001.
She is also a member of the Biotechnology Committee in FICCI (Federation of Indian Chambers of Commerce and Industry) and CII (Confederation of Indian Industry).
|
 Martine Denis,
Director, Influenza Vaccine Projects Strategy,
GlaxoSmithKline Biologicals, Belgium
Dr. Martine Denis, DVM, is Director, Influenza Vaccine Projects Strategy, at GlaxoSmithKline Biologicals. She has been in charge of the coordination of new influenza vaccine development at GlaxoSmithKline since Dec 2004. Her professional experience at the same company includes positions as the head of HIV Immunology, head of Clinical Immunology Viral Vaccines, head of Preclinical Virology Herpes Viruses. She also led the Vaccine Development activities at Henogen, a Belgian Biotechnology company. Dr. Denis has been a member of the faculty of Veterinary Medicine, Department of Immunology-Vaccinology at the University of Liège, Belgium.
Over the past twelve years, Dr. Denis contributed to a variety of virus vaccine projects at various stages of development from early research to post-marketing activities. Dr. Denis is the author of numerous publications on virus vaccines
|
 Elaine Esber,
Executive Director, Medical Affairs International, Merck Vaccine Division,
Merck & Co, USA
Elaine C. Esber, M.D., is a pediatrician with a subspecialty in Pediatric Hematology and Oncology.
She joined Merck & Co., Inc., in April 2001, as Executive Director, Medical Affairs International in the Merck Vaccine Division (MVD). In this capacity, she represents MVD with international organizations, including the World Health Organization (WHO), the Global Alliance for Vaccines and Immunization (GAVI), the Pan American Health Organization (PAHO), the International Association for Biologics (IABs), as well as numerous other international organizations. She represents Merck &Co, Inc. on the Ad Hoc Industry Group that discusses GAVI policy and activities, serves in support of the GAVI Board member (a position currently held by the Merck Vaccine President) , as well as on the IFFIm Task Team, among others. She Chairs the International Federation of Pharmaceutical Manufacturers Association’s (IFPMA) Biologics and Vaccines’ Committee and serves as the industry member of the Strategic Advisory Group of Experts (SAGE) of the WHO as well as representing the biologics industry on behalf of IFPMA. Dr. Esber also directs the Merck Vaccine Network – Africa Program (MVN-A) for the Merck Company Foundation. The project is aimed at developing training centers in Africa in support of immunization efforts of GAVI. In addition, she is frequently called upon to make presentations on vaccines, immunization, regulatory and other related topics.
|
 Catarina Flyborg,
Head, Vaccine Initiative,
GE Healthcare Life Sciences
Catarina is the leader of the Vaccine Initiative within GE Healthcare Life Sciences, a $ 1,2 million global business within GE Healthcare. GEHC Life Sciences supplies technologies and services to biotech manufacturing and research.
Prior to her current role she held a position as Head of Communications for GEHC Life Sciences. Catarina has a long experience from the life sciences market and has worked for Pharmacia Biotech for many years holding various management positions within marketing and product management. Before joining GE she worked with business development at the advertising agency Dowell/Stubbs. Catarina holds a MSc in Biochemical Engineering from the Royal Institute of Technology.
|
 Jean Francois Biry,
Chief Executive Officer,
DBV Technologies, France
|
 Alex Von Gabain,
Chief Scientific Officer,
Intercell, Austria
|
 N K Ganguly,
Director General,
Indian Council of Medical Research, India
Prof.N.K.Ganguly did his MBBS from University of Kolkatta, MD (Microbiology) from Post Graduate Institute of Medical Education & Research, Chandigarh and obtained D.Sc. (h.c.) from Bundelkhand University, Jhansi; Chhatrapati Shahu Ji Maharaj University, Kanpur and University of Calcutta, Kolkata. Currently, he is Director General, Indian Council of Medical Research, New Delhi.
Prof.Ganguly has published 500 papers and guided 100 Ph.D thesis as guide/co-guide. His major research areas have been tropical diseases, cardiovascular diseases and diarrhoeal diseases. His area of specialization is infection and has interests in this area ranges from immunology, biotechnology and public health. He has won 90 awards (International-3; National-87
|
 Dr Lallan Giri,
Vice President, Scientific and Regulatory Affairs,
Emergent Biosolutions
Currently Vice President of Scientific Affairs. Manages scientific and technology aspects in the commercial development of vaccines, evaluation and in-licensing of technology, and identifies potential candidates for collaborations, partnership, and merger and acquisition.
Formerly he was responsible for Research and Development, Regulatory Affairs, and Quality Operations at BioPort Corporation, Lansing, Michigan site. He led a team at the Bioport Coporation, Lansing, Michigan to the successful approval of the Anthrax vaccine manufacturing facility and BLA. Before joining BioPort Corporation in 2000 he held the position of Executive Director of Quality Operations and Regulatory Affairs (1993 -1999) at the Glaxo Wellcome Biopharmaceutical Inc (GWBI) and was responsible for getting the GWBI approved by FDA for the manufacture and distribution of a – interferon (Wellferon™) for Hepatitis C indication. He also held the position of Director of Analytical Development and Quality Control at the Aventis Pasteur
( formerly Pasteur Merieux Connaught ), in the US (1989-1993). While in this position played a key role in the development and licensing of five vaccines for adult and pediatric indications.
Earned a Ph. Degree in Biological Sciences from the University of Montana (1974), U.S.A. and Post-Doctoral training in protein chemistry from the Max Planck Institute of Molecular Genetics, Germany (1975-1978). Held academic appointment at the University of Massachusetts in Biochemistry (1979-1983) where he taught Biochemistry and conducted research RNA – Protein interaction and structure and function of Ribosomes. He then took his first Industrial position as Manager of R&D in Pharmacia, USA where he led a team in peptide and DNA synthesis and purification research (1983-1989). In total, Dr. Giri has 23 years of Biopharmaceutical industry plus 8 years of academic (research and teaching) experience.
|
 Jaap Goudsmit,
Chief Scientific Officer,
Crucell, The Netherlands
|
 Rajat Goyal,
Project Director, Advancing Rotavirus Vaccine Development,
PATH, India
Dr. Rajat Goyal, MD is Director for Advancing Rotavirus Vaccine Development (ARVAC) Project at PATH,
an international, nonprofit organization dedicated to improving the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors. ARVAC is a five year project funded by the Bill & Melinda Gates Foundation to advance the development and introduction of the UK-Bovine human reassortant vaccine to reduce the deaths and hospitalizations in the developing world due to severe rotavirus infection.
Prior to moving full time to ARVAC project, Dr. Goyal led the Vaccines & Health Technologies portfolio at PATH in India looking after a wide range of new vaccine and other health technology projects in various stages of development - right from product development to regulatory approvals.
During his tenure at PATH, Dr. Goyal has been responsible for strengthening PATH’s relationships with government and regulatory bodies, academic / research institutions, biotechnology, medical device and pharmaceutical companies. His leadership has also increased the diversity in PATH’s new vaccine and health technology portfolio and has helped launch innovative projects.
Before joining PATH, Dr. Goyal was the Vice President of Reliance Industries Limited (RIL) heading the Reliance Clinical Research Services (RCS) at Mumbai, India setting up and establishing the clinical research activities for India’s largest industrial conglomerate. Dr. Goyal led preclinical and clinical research for various drugs, vaccines and other biotechnology products during this period. Dr. Goyal also led Reliance’s work in life sciences with research on stem cell and tissue engineering. Dr. Goyal’s other experience includes product development and clinical research with Dabur, a leading oncology product manufacturer in India and as a consultant hemato-oncologist with leading hospitals..
Dr. Goyal received his basic medical degree from King Edwards Memorial Hospital in Mumbai in 1990 and received MD (postgraduate) in 1993 specializing in pathology at Haffkine Institute of Research & Training in Mumbai. He was a visiting fellow at Harvard Medical School and Rush Cancer Institute.
|
Roland Heinrich,
Vice President, Bioprocess R&D,
Millipore, USA
|
 Julie Jacobson,
Scientific Officer, Immunization Solutions, Director, JE Project,
PATH, USA
Julie Jacobson, director of PATH’s Japanese Encephalitis (JE) Project, oversees a US$35 million grant to accelerate the control of JE in endemic countries through improving surveillance data, the development of an improved vaccine and diagnostic tests for JE, and to help countries integrate JE vaccine into immunization programs. Previously, she worked on PATH’s Children’s Vaccine Project (CVP) with yellow fever and rotavirus vaccines from clinical studies through implementation. Prior to joining PATH, Dr. Jacobson was an epidemic intelligence officer at the U.S. Centers for Disease Control and Prevention (CDC). Dr. Jacobson is a physician with training in clinical tropical medicine and applied epidemiology.
|
 Suresh Jadhav,
Executive Director, Quality Control,
Serum Institute of India Ltd, India
|
 Jeong Jin Lee,
Head of Vaccines, R&D,
LG Life Sciences, Korea
|
Nyoman Kandun,
Director General, Communicable Disease Control and Environmental Health,
Ministry of Health, Indonesia
|
Kanwarjit KJ Singh,
Senior Programme Officer,
Bill and Melinda Gates Foundation, USA
|
Peter Koury,
Vice President, Global Marketing,
Baxter Vaccines, USA
|
 Wang Li Feng,
Chief Executive Officer,
China National Biotec Group (CNBG), China
Mrs. WANG Lifeng is President and CEO of China National Biotec Group (CNBG), a position she has held since July 2006, and has been serving within CNBG for more than 30 years. Prior to her current position, Mrs. WANG was the director of Chengdu Institute of Biological Products (CDIBP), one of 6 institutes of CNBG from July 2003 and led CDIBP to overcome various difficulties and become an institute with excellent performance in R&D, operation and especially in international business. Previously, Mrs. WANG held various positions in Shanghai Institute of Biological Products (SIBP), another institute of CNBG, with escalated responsibilities such as Deputy Director, Party Secretary, etc.
|
Yang Lingjiang,
Head, International Business and Co-operation,
Chengdu Institute of Biological Products, China
|
 Jacques-Francois Martin,
President,
Parteurop, France
Jacques-François Martin has spent the essence of his career in the pharmaceutical, biological and life sciences industries.
From 1970 until 1976, he was the Chief Executive Officer of Rhône-Poulenc Pharma in Hamburg, Germany. Martin then returned to France to join the Institut Mérieux as Vice President of sales and marketing, where he largely contributed to the international expansion of Mérieux. He was named the company’s Chief Executive Officer in 1988, and successfully negotiated with the government of Canada to acquire Connaught Laboratories.
In 1991, Martin set up Parteurop S.A, a biotech consulting company based in Lyon, France. At Parteurop, Martin as Chairman and CEO, helps establish start-up companies by leveraging innovation from French and foreign institutions.
From 1996 to 1998, Martin was the Chief Executive Officer of the Fondation Jean Dausset – Centre d’Etudes du Polymorphisme Humain, a private foundation dedicated to genomics research.
From September 1996 to September 1999, he was a member of the Board of INSERM (Institut National de la Santé et de la Recherche Médicale, the French National Institute of Health).
From 1994 to 1997, Martin served as the Chairman of the Biologicals Committee of the International Federation of Pharmaceutical Manufacturers Associations. As such, he was a member of the Scientific Advisory Group of Experts of WHO (SAGE).
From November 1997 to June 2003 he was a member of the Board of the International AIDS Vaccine Initiative (IAVI).
From 2000 to January 2005, Martin held the position of President of The Vaccine Fund. He lead the Fund’s efforts to provide lifesaving vaccines and other immunization program support to low-income countries. In this capacity, he was also a member of the Board of GAVI (Global Alliance for Vaccines and Immunization).
He is member of the Board of several life sciences companies. Martin holds a Master’s in Business Administration from the Ecole des Hautes Etudes Commerciales.
|
John McNeil,
Scientific Director,
Malaria Vaccine Initiative, PATH, USA
|
Gary Van Next,
Vice President, Preclinical Development,
Dynavax, USA
|
Ann O'Hara,
General Manager, Bioprocess,
GE Healthcare, Sweden
|
 Nobuhiko Okabe,
Director, Infectious Disease Surveillance Center,
National Institute of Infectious Disease, Japan
|
 Nikolai Petrovsky,
Chairman,
Vaxine, Australia
|
 Helene Pora,
Vaccine Application Development Director,
Pall Life Sciences, France
Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.
|
 G S Reddy,
Chief General Manager,
Indian Immunologicals, India
Dr.G.S.Reddy is the Chief General Manager of Indian Immunologicals Limited, a major veterinary and human vaccines manufacturer in India. He obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad.
He has 25 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and Regulatory affairs. He is heading the team which is involved in manufacturing of various veterinary biologicals and human vaccines such as recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention(CDC), Atlanta, USA. He is co-author of patent on DNA Rabies vaccine. He has published 40 scientific papers in various journals.
|
 Vijay B Samant,
Chief Executive Officer,
VICAL, USA
Vijay B. Samant joined Vical as President and Chief Executive Officer in November 2000. Mr. Samant had 23 years of diverse U.S. and international sales, marketing, operations, and business development experience with Merck.
From 1998 to mid-2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs, and Executive Director of Materials Management. Mr. Samant earned his M.B.A.
from the Sloan School of Management at the Massachusetts Institute of Technology in 1983. He received a master's degree in chemical engineering from Columbia University in 1977 and a bachelor's degree in chemical engineering from the University of Bombay, University Department of Chemical Technology, in 1975.
|
 Douglas Thomson,
Chief Executive Officer,
Singvax, Singapore
|
 Richard Van Duyse,
Chief Operating Officer,
Tianyuan Biopharmaceutical Co. Ltd, China
Richard van Duyse, Dutch nationality, joined in 2005 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd, Hangzhou, China; a private vaccine manufacturing and sales company.
As COO, he is responsible for all operations and for ‘the internationalization processes’ in particularly aspects such as (GMP) quality, technology transfer, (project) management style, documentation, regulatory, etc. to ensure a sustainable development of Tianyuan.
Prior to joining Tianyuan, Richard van Duyse worked in RIVM and SVM (Director of Operations) in the Netherlands for over 25 years, respectively for Perfetti-vanMelle (General Manager) and Jacobs Engineering (Senior Consultant / Director Pharma Northern Europe), gaining broad professional, management and consultancy experience. Responsibilities during that time included production, project management and business development, through a number of assignments oversea and at country offices.
He is a graduate of Den Bosch University of Technology (The Netherlands).
|
V K Vinayak,
President, Biopharmaceutical R&D,
Panacea Biotec, India
|
 Sy-dar Wang,
Chief Technology Officer, Acting CEO,
Adimmune, Taiwan
|
Dr Mansour Yaich,
Vaccine Development Director,
PATH
Mansour Yaich, Vaccine Development Director at PATH, is responsible for establishing and implementing the project's vaccine development agenda. Streamlining the process to move JE vaccine candidates through regulatory approval by health authorities, Dr.Yaich's responsibilities are wide-ranging from initiating clinical trial activities and establishing partnerships with vaccine manufacturers to negotiating contracts and selecting service companies. Coordinating these elements and overseeing their implementation is a delicate balance that draws upon Dr Yaich's experience in the pharmaceutical industry, where he tackled the complexities of vaccine development and clinical trials across four continents before joining PATH in October 2004. At Sanofi Pasteur, he served for eight years as Global Clinical Regulatory Officer and Project Team Leader for several new viral and bacterial vaccine candidates. Previously, he spent one year in the experimental virology unit at the Pasteur Institute, honing skills in molecular biology and cellular virology. Outside of the lab, Dr. Yaich developed a drug-testing unit specializing in pediatric infectious disease at the Clinical Pharmacology Unit of General Infant Robert Debre Hospital in Paris.
|
Dr John Yang,
Asia Pacific Regional Medical Director,
Merck Vaccines Taiwan
Dr John Yang is currently the Asia-Pacific Medical Director in the Policy, Public Health & Medical Affairs, Vaccine Division, of Merck Corp. He is also Adjunct Associate Professor at the School of Public Health and School of Health Affairs Management, National Yang-Ming University.
Dr Yang received his Bachelor of Medicine from Taipei Medical College in 1983 and in 1988 he began doctoral studies on the development and application of immunoassays for biological monitoring of aflatoxin exposure in humans. Dr Yang was awarded his doctorate from Columbia University School of Public Health (New York) in 1990.
Beginning as an attending physician in the Division of Clinical Toxicology at the Department of Medicine, Taipei Veterans General Hospital (1990), Dr Yang has held positions as Deputy Director (Keelung Hospital, 1997) and Chancellor (I-Lan Hospital, 1999) both in Taiwan. He then was a Senior Researcher and Chief at the Department of Medical Service Quality, Bureau of National Health Insurance. In 2001, Dr Yang joined Merck Corp. as Medical Advisor.
|
 Jiansan Zhang,
Vice President, Production, Engineering, Development and Quality Assurance,
Sinovac Biotech, China
|
|
|
|
